Views: 0 Author: Site Editor Publish Time: 2026-07-21 Origin: Site
News Release – July 21, 2026
On July 6, 2026, the National Medical Products Administration (NMPA), the Ministry of Public Security, and the National Health Commission jointly issued the Announcement on Adjusting the List of Pharmaceutical Psychotropic Substances (No. 58 of 2026), deciding to add three varieties – methoxyetomidate, loretomidate, and suanfento (etomidate analogues) – to the pharmaceutical psychotropic substances list, effective October 1, 2026.
The announcement is made in accordance with the Regulations on the Administration of Narcotic Drugs and Psychotropic Substances. The three newly added varieties are structurally similar to etomidate and have been prominent in non‑medical misuse in recent years. Once added, the production, trade, use, storage, and transportation of these substances will be subject to full‑chain control under psychotropic substance regulations.
China maintains a strict classified management system for psychotropic substances. In recent years, certain new psychoactive substances (NPS) have entered the market as "legal substitutes," creating regulatory gaps due to their absence from controlled lists. Adding methoxyetomidate and the other two varieties to the pharmaceutical psychotropic substances list is a timely measure to align legislation with regulatory needs and close loopholes for drug abuse. The nearly three‑month transition period from the announcement date (July 6) to the implementation date (October 1) provides essential time for relevant enterprises to complete compliance adjustments.
For API and formulation manufacturers, supply chain management, storage conditions, and procurement/distribution channels for the newly listed varieties must be upgraded to meet psychotropic substance requirements. CRO/CDMO service providers involved in R&D projects containing related compounds will need to reassess compliance pathways and qualification alignment.
Bestcomm will continue to monitor updates to the pharmaceutical psychotropic substances list, strictly adhere to the latest control requirements in its API R&D and formulation development services, and safeguard partner projects and product launches through robust compliance capabilities.
